Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.

Criss SD, Mooradian MJ, Watson TR, Gainor JF, Reynolds KL, Kong CY.

JAMA Netw Open. 2019 Sep 4;2(9):e1911952. doi: 10.1001/jamanetworkopen.2019.11952.

PMID:
31553470
2.

Time to tackle the blood-brain barrier in HER2-mutant lung cancer.

Lin JJ, Gainor JF.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32460. [Epub ahead of print] No abstract available.

PMID:
31469415
3.

Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RI, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM.

Ann Oncol. 2019 Aug 21. pii: mdz288. doi: 10.1093/annonc/mdz288. [Epub ahead of print]

PMID:
31435660
4.

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity.

Dagogo-Jack I, Rooney M, Lin JJ, Nagy RJ, Yeap BY, Hubbeling H, Chin E, Ackil J, Farago AF, Hata AN, Lennerz JK, Gainor JF, Lanman RB, Shaw AT.

Clin Cancer Res. 2019 Jul 29. doi: 10.1158/1078-0432.CCR-19-1436. [Epub ahead of print]

PMID:
31358542
5.

A coming of age for immune checkpoint inhibitors in cancer.

Nipp RD, Gainor JF.

Immunotherapy. 2019 Jun;11(8):647-650. doi: 10.2217/imt-2019-0066. No abstract available.

6.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
7.

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.

Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J.

Ann Oncol. 2019 Jul 1;30(7):1134-1142. doi: 10.1093/annonc/mdz113.

PMID:
30918950
8.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O'Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS.

J Clin Oncol. 2019 Apr 20;37(12):992-1000. doi: 10.1200/JCO.18.01042. Epub 2019 Feb 20.

PMID:
30785829
9.

Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC.

Dagogo-Jack I, Rooney M, Nagy RJ, Lin JJ, Chin E, Ferris LA, Ackil J, Lennerz JK, Lanman RB, Gainor JF, Shaw AT.

J Thorac Oncol. 2019 May;14(5):816-824. doi: 10.1016/j.jtho.2019.01.009. Epub 2019 Jan 18.

PMID:
30664990
10.

Hospice use and end-of-life care among older patients with esophageal cancer.

Tramontano AC, Nipp R, Kong CY, Yerramilli D, Gainor JF, Hur C.

Health Sci Rep. 2018 Jul 19;1(9):e76. doi: 10.1002/hsr2.76. eCollection 2018 Sep.

11.

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.

Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY.

JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449.

PMID:
30543349
12.

Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.

Lin JJ, Jiang GY, Joshipura N, Ackil J, Digumarthy SR, Rincon SP, Yeap BY, Gainor JF, Shaw AT.

J Thorac Oncol. 2019 Apr;14(4):683-690. doi: 10.1016/j.jtho.2018.12.002. Epub 2018 Dec 7.

PMID:
30529198
13.

Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer.

Lichtenstein MRL, Nipp RD, Muzikansky A, Goodwin K, Anderson D, Newcomb RA, Gainor JF.

J Thorac Oncol. 2019 Mar;14(3):547-552. doi: 10.1016/j.jtho.2018.11.011. Epub 2018 Nov 23.

PMID:
30476576
14.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR.

Semin Arthritis Rheum. 2019 Jun;48(6):1127-1132. doi: 10.1016/j.semarthrit.2018.10.012. Epub 2018 Oct 16.

PMID:
30409415
15.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

16.

Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.

Dagogo-Jack I, Stevens SE, Lin JJ, Nagy R, Ferris L, Shaw AT, Gainor JF.

J Thorac Oncol. 2018 Nov;13(11):e226-e227. doi: 10.1016/j.jtho.2018.06.021. No abstract available.

PMID:
30368414
17.

Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.

Zhang ML, Kem M, Mooradian MJ, Eliane JP, Huynh TG, Iafrate AJ, Gainor JF, Mino-Kenudson M.

Mod Pathol. 2019 Apr;32(4):511-523. doi: 10.1038/s41379-018-0160-1. Epub 2018 Oct 26.

PMID:
30367104
18.

Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss.

Neilan TG, Price MC, Sanborn DY, Gainor JF, Chen A.

N Engl J Med. 2018 Oct 25;379(17):1658-1669. doi: 10.1056/NEJMcpc1802830. No abstract available.

PMID:
30354952
19.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions.

Piotrowska Z, Costa DB, Oxnard GR, Huberman M, Gainor JF, Lennes IT, Muzikansky A, Shaw AT, Azzoli CG, Heist RS, Sequist LV.

Ann Oncol. 2018 Oct 1;29(10):2092-2097. doi: 10.1093/annonc/mdy336.

PMID:
30351341
20.

Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

Chu JN, Choi J, Ostvar S, Torchia JA, Reynolds KL, Tramontano A, Gainor JF, Chung DC, Clark JW, Hur C.

Cancer. 2019 Jan 15;125(2):278-289. doi: 10.1002/cncr.31795. Epub 2018 Oct 21.

PMID:
30343509
21.

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV.

Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.

PMID:
30257958
22.

Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

Nangia V, Siddiqui FM, Caenepeel S, Timonina D, Bilton SJ, Phan N, Gomez-Caraballo M, Archibald HL, Li C, Fraser C, Rigas D, Vajda K, Ferris LA, Lanuti M, Wright CD, Raskin KA, Cahill DP, Shin JH, Keyes C, Sequist LV, Piotrowska Z, Farago AF, Azzoli CG, Gainor JF, Sarosiek KA, Brown SP, Coxon A, Benes CH, Hughes PE, Hata AN.

Cancer Discov. 2018 Dec;8(12):1598-1613. doi: 10.1158/2159-8290.CD-18-0277. Epub 2018 Sep 25.

PMID:
30254092
23.

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.

Lin JJ, Chin E, Yeap BY, Ferris LA, Kamesan V, Lennes IT, Sequist LV, Heist RS, Mino-Kenudson M, Gainor JF, Shaw AT.

J Thorac Oncol. 2019 Jan;14(1):135-140. doi: 10.1016/j.jtho.2018.09.001. Epub 2018 Sep 8.

PMID:
30205166
24.

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.

Chaft JE, Dagogo-Jack I, Santini FC, Eng J, Yeap BY, Izar B, Chin E, Jones DR, Kris MG, Shaw AT, Gainor JF.

Lung Cancer. 2018 Aug;122:67-71. doi: 10.1016/j.lungcan.2018.05.020. Epub 2018 May 22.

25.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

26.

Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.

Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ.

J Thorac Oncol. 2018 Oct;13(10):1530-1538. doi: 10.1016/j.jtho.2018.06.005. Epub 2018 Jun 20.

27.

ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?

Piotrowska Z, Gainor JF.

J Clin Oncol. 2018 Aug 1;36(22):2241-2243. doi: 10.1200/JCO.2018.79.3059. Epub 2018 Jun 4. No abstract available.

PMID:
29864378
28.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

29.

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.

Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM.

J Clin Oncol. 2018 Jul 1;36(19):1905-1912. doi: 10.1200/JCO.2017.77.0305. Epub 2018 May 10.

30.

Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.

Schapira E, Hubbeling H, Yeap BY, Mehan WA Jr, Shaw AT, Oh K, Gainor JF, Shih HA.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):624-629. doi: 10.1016/j.ijrobp.2018.02.175. Epub 2018 Mar 22.

PMID:
29678530
31.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK.

Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.

32.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, Dardaei L, Prutisto-Chang K, Dagogo-Jack I, Timofeevski S, Hubbeling H, Gainor JF, Ferris LA, Riley AK, Kattermann KE, Timonina D, Heist RS, Iafrate AJ, Benes CH, Lennerz JK, Mino-Kenudson M, Engelman JA, Johnson TW, Hata AN, Shaw AT.

Cancer Discov. 2018 Jun;8(6):714-729. doi: 10.1158/2159-8290.CD-17-1256. Epub 2018 Apr 12.

33.

Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.

Gainor JF.

J Thorac Dis. 2018 Jan;10(1):25-29. doi: 10.21037/jtd.2017.12.23. No abstract available.

34.

ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?

Lin JJ, Gainor JF.

Lancet Oncol. 2018 Apr;19(4):438-439. doi: 10.1016/S1470-2045(18)30160-8. Epub 2018 Mar 12. No abstract available.

PMID:
29545096
35.

Putting the brakes on CTLA-4 inhibition in lung cancer?

Mooradian MJ, Gainor JF.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S35-S38. doi: 10.21037/tlcr.2018.01.05. No abstract available.

36.

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.

Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA.

Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5.

37.

Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.

Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, Oh KS, Shaw AT, Mehan WA, Shih HA, Gainor JF.

J Thorac Oncol. 2018 Apr;13(4):550-558. doi: 10.1016/j.jtho.2018.01.012. Epub 2018 Jan 31.

38.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, Ackil J, Stevens S, Dardaei L, Yoda S, Hubbeling H, Digumarthy SR, Riester M, Hata AN, Sequist LV, Lennes IT, Iafrate AJ, Heist RS, Azzoli CG, Farago AF, Engelman JA, Lennerz JK, Benes CH, Leary RJ, Shaw AT, Gainor JF.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00160. Epub 2018 Jan 23.

39.

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI.

J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26.

40.

Keeping Expectations in Check With Immune Checkpoint Inhibitors.

Temel JS, Gainor JF, Sullivan RJ, Greer JA.

J Clin Oncol. 2018 Jun 10;36(17):1654-1657. doi: 10.1200/JCO.2017.76.2146. Epub 2018 Jan 25. No abstract available.

PMID:
29369730
41.

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD.

J Clin Oncol. 2018 Mar 1;36(7):633-641. doi: 10.1200/JCO.2017.75.3384. Epub 2018 Jan 16. Erratum in: J Clin Oncol. 2018 Jun 1;36(16):1645.

42.

Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.

Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16.

43.

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Kodack DP, Farago AF, Dastur A, Held MA, Dardaei L, Friboulet L, von Flotow F, Damon LJ, Lee D, Parks M, Dicecca R, Greenberg M, Kattermann KE, Riley AK, Fintelmann FJ, Rizzo C, Piotrowska Z, Shaw AT, Gainor JF, Sequist LV, Niederst MJ, Engelman JA, Benes CH.

Cell Rep. 2017 Dec 12;21(11):3298-3309. doi: 10.1016/j.celrep.2017.11.051.

44.

Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings.

Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, Fintelmann FJ.

Radiographics. 2017 Nov-Dec;37(7):2132-2144. doi: 10.1148/rg.2017170085. Review.

PMID:
29131763
45.

Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC.

Elife. 2017 Oct 31;6. pii: e33173. doi: 10.7554/eLife.33173. No abstract available.

46.

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.

Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ.

Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.

47.

Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy.

Hwang WL, Niemierko A, Hwang KL, Hubbeling H, Schapira E, Gainor JF, Keane FK.

JAMA Oncol. 2018 Feb 1;4(2):253-255. doi: 10.1001/jamaoncol.2017.3808. No abstract available.

48.

Fast, Food and Ceritinib in ALK-Positive NSCLC.

Gainor JF, Shaw AT.

J Thorac Oncol. 2017 Sep;12(9):1341-1343. doi: 10.1016/j.jtho.2017.07.012. No abstract available.

49.

Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.

Wang GX, Guo LQ, Gainor JF, Fintelmann FJ.

AJR Am J Roentgenol. 2017 Sep;209(3):567-575. doi: 10.2214/AJR.16.17770. Epub 2017 Jun 28. Review.

PMID:
28657846
50.

ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack.

Mooradian MJ, Gainor JF.

Oncologist. 2017 Jul;22(7):759-761. doi: 10.1634/theoncologist.2017-0178. Epub 2017 Jun 22. No abstract available.

Supplemental Content

Loading ...
Support Center